CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
ACO REACH revenue	$ 896,504,000	$ 654,087,000
Investment income (loss)	86,000	(55,429,000)
Total revenue	1,160,802,000	751,163,000
Operating expenses:
Medical costs	996,582,000	662,972,000
Operating costs	287,138,000	354,436,000
Bad debt expense	27,407,000	12,000
Restructuring charges	6,990,000	29,178,000
Goodwill impairment	401,385,000	0
Intangible assets impairment	0	42,611,000
Depreciation and amortization	18,296,000	30,710,000
Total operating expenses	1,737,798,000	1,119,919,000
Operating loss	(576,996,000)	(368,756,000)
Interest expense	38,203,000	12,822,000
Warrant expense	13,971,000	0
Loss from continuing operations before income taxes	(629,170,000)	(381,578,000)
Income tax expense (benefit)	(1,428,000)	3,664,000
Net loss from continuing operations	(627,742,000)	(385,242,000)
Loss from discontinued operations, net of tax (Note 19)	(638,066,000)	(974,638,000)
Net loss	(1,265,808,000)	(1,359,880,000)
Net loss (earnings) from continuing operations attributable to noncontrolling interests	114,354,000	(95,664,000)
Net loss attributable to NeueHealth, Inc. common shareholders	$ (1,200,599,000)	$ (1,495,231,000)
Continuing operations, basic (in dollars per share)	$ (70.72)	$ (66.17)
Continuing operations, diluted (in dollars per share)	(70.72)	(66.17)
Discontinued operations, basic (in dollars per share)	(80.22)	(123.87)
Discontinued operations, diluted (in dollars per share)	(80.22)	(123.87)
Basic loss per share (in dollars per share)	(150.94)	(190.04)
Diluted loss per share (in dollars per share)	$ (150.94)	$ (190.04)
Basic weighted-average common shares outstanding (in shares)	7,954	7,868
Diluted weighted-average common shares outstanding (in shares)	7,954	7,868
Capitated revenue
Revenue:
Revenue	$ 219,774,000	$ 112,904,000
Service revenue
Revenue:
Revenue	44,438,000	39,601,000
Series A Preferred Stock
Operating expenses:
Series A and B preferred stock dividend accrued	(40,139,000)	(37,889,000)
Series B Preferred Stock
Operating expenses:
Series A and B preferred stock dividend accrued	$ (9,006,000)	$ (1,798,000)